Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
110 tokens/sec
GPT-4o
56 tokens/sec
Gemini 2.5 Pro Pro
44 tokens/sec
o3 Pro
6 tokens/sec
GPT-4.1 Pro
47 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases (2010.06430v2)

Published 13 Oct 2020 in stat.ME and stat.ML

Abstract: The Predictive Approaches to Treatment Effect Heterogeneity statement focused on baseline risk as a robust predictor of treatment effect and provided guidance on risk-based assessment of treatment effect heterogeneity in the RCT setting. The aim of this study was to extend this approach to the observational setting using a standardized scalable framework. The proposed framework consists of five steps: 1) definition of the research aim, i.e., the population, the treatment, the comparator and the outcome(s) of interest; 2) identification of relevant databases; 3) development of a prediction model for the outcome(s) of interest; 4) estimation of relative and absolute treatment effect within strata of predicted risk, after adjusting for observed confounding; 5) presentation of the results. We demonstrate our framework by evaluating heterogeneity of the effect of angiotensin-converting enzyme (ACE) inhibitors versus beta blockers on three efficacy and six safety outcomes across three observational databases. The proposed framework can supplement any comparative effectiveness study. We provide a publicly available R software package for applying this framework to any database mapped to the Observational Medical Outcomes Partnership Common Data Model. In our demonstration, patients at low risk of acute myocardial infarction received negligible absolute benefits for all three efficacy outcomes, though they were more pronounced in the highest risk quarter, especially for hospitalization with heart failure. However, failing diagnostics showed evidence of residual imbalances even after adjustment for observed confounding. Our framework allows for the evaluation of differential treatment effects across risk strata, which offers the opportunity to consider the benefit-harm trade-off between alternative treatments.

User Edit Pencil Streamline Icon: https://streamlinehq.com
Authors (6)
  1. Alexandros Rekkas (2 papers)
  2. David van Klaveren (3 papers)
  3. Patrick B. Ryan (6 papers)
  4. Ewout W. Steyerberg (11 papers)
  5. David M. Kent (5 papers)
  6. Peter R. Rijnbeek (5 papers)
Citations (5)

Summary

We haven't generated a summary for this paper yet.